|
Myeloid Leukemia, Chronic
|
|
0.710 |
GeneticVariation
|
BEFREE |
Missense mutations of A300V, V402M, and R415H in LNK were found in 8 patients including ET (4 cases, all combined with JAK2-V617F mutation), PV (2 cases, one combined with JAK2-V617F mutation), PMF (one case, combined with JAK2-V617F mutation) and CML (one case, combined with BCR/ABL1 fusion gene).
|
27111338 |
2016 |
|
Myeloid Leukemia, Chronic
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Myeloid Leukemia, Chronic
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
|
23676790 |
2013 |
|
Myeloid Leukemia, Chronic
|
|
0.710 |
GeneticVariation
|
CLINVAR |
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
|
21489624 |
2011 |
|
Myeloid Leukemia, Chronic
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
|
19811824 |
2010 |
|
Myeloid Leukemia, Chronic
|
|
0.710 |
GeneticVariation
|
CLINVAR |
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
|
14745431 |
2004 |
|
Myeloid Leukemia, Chronic
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
|
12623848 |
2003 |
|
Myeloid Leukemia, Chronic
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
|
12399961 |
2002 |
|
Thrombocythemia, Essential
|
|
0.010 |
GeneticVariation
|
BEFREE |
Missense mutations of A300V, V402M, and R415H in LNK were found in 8 patients including ET (4 cases, all combined with JAK2-V617F mutation), PV (2 cases, one combined with JAK2-V617F mutation), PMF (one case, combined with JAK2-V617F mutation) and CML (one case, combined with BCR/ABL1 fusion gene).
|
27111338 |
2016 |